Clinical effect of atorvastatin-trimetazidine combined treatment of coronary heart disease

Song, Ji Dong; Wang, Li Li

doi:10.4066/biomedicalresearch.29-17-3469

Cited by 1 publication

(1 citation statement)

References 6 publications

(6 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The combination therapy based on ATOR and TMZ could provide an effective improvement on cardiac functions; reduces the level of inflammatory factors and improves the endothelial function in patients with coronary heart disease which greatly reduce the risk of myocardial injury and enhance cure rates (Tian, 2016, Lin et al, 2013). Hence, combining both ATOR and TMZ into a single formulation will be beneficial for patients with coronary heart disease and can minimize the prevalence of postoperative myocardial injury as well as effectively improve their lipid profile (Song and Wang, 2018, Wang et al, 2018, Xu et al, 2017).…”

Section: Introductionmentioning

confidence: 99%

Novel sublingual tablets of Atorvastatin calcium/Trimetazidine hydrochloride combination; HPTLC quantification, in vitro formulation and characterization

Atia

Tawfeek

Rageh

et al. 2019

Saudi Pharmaceutical Journal

View full text Add to dashboard Cite

BackgroundIschemic heart disorders and accumulation of lipids in blood vessels could contribute to angina pectoris. Therefore, the aim of this study was to formulate sublingual tablets containing a novel combination of Atorvastatin calcium (ATOR) and Trimetazidine HCl (TMZ) for efficient treatment of coronary heart disorders.MethodsThe dissolution rate of water-insoluble ATOR was enhanced via complexation with sulfobutyl ether-β-cyclodextrin (SBE-β-CD) and addition of soluplus as a polymeric solubilizer excipient. The solubilized ATOR and TMZ were compressed into a sublingual tablets by direct compression technique and evaluated for their tableting characteristics. In addition, a new validated method based on High Performance Thin Layer Chromatography (HPTLC) was developed for simultaneous determination of both drugs in pure forms and sublingual tablets.ResultsThe developed HPTLC method showed LODs of 0.056 and 0.013 μg/band and LOQs of 0.17, 0.040 μg/band for TMZ and ATOR, respectively and proved to be linear, accurate, precise and robust. The optimum formulation containing mixture of superdisintegrants; Ac-Di-Sol and crospovidone (4.8% w/w, each) showed the shortest disintegration time (65 s) and enhanced release profiles of both drugs.ConclusionsThe prepared sublingual tablets combining ATOR and TMZ will be a promising dosage form for coronary heart disease patients with an instant action and improved patient compliance.

show abstract

Section: Introductionmentioning

confidence: 99%

Novel sublingual tablets of Atorvastatin calcium/Trimetazidine hydrochloride combination; HPTLC quantification, in vitro formulation and characterization

Atia

Tawfeek

Rageh

et al. 2019

Saudi Pharmaceutical Journal

View full text Add to dashboard Cite

show abstract

Clinical effect of atorvastatin-trimetazidine combined treatment of coronary heart disease

Abstract: Objective: To explore clinical effect of atorvastatin-trimetazidine combined treatment of patients with coronary heart diseases. Methodology: A total of 98 patients with coronary heart diseases accepted by our hospital from

Cited by 1 publication

References 6 publications

Novel sublingual tablets of Atorvastatin calcium/Trimetazidine hydrochloride combination; HPTLC quantification, in vitro formulation and characterization

Novel sublingual tablets of Atorvastatin calcium/Trimetazidine hydrochloride combination; HPTLC quantification, in vitro formulation and characterization

Contact Info

Product

Resources

About